Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | WIZ | O95785 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787023 | 0.86 | CYP2C9 (0.49) | MAOACYP2C9ADRA1AHRH1 | |
| SCHEMBL31409498 | 0.81 | HTR2A (0.53) | SCN1ASCN5ASCN9AMAOACYP2C9 | |
| SCHEMBL804658 | 0.79 | CYP2C9 (0.64) | MAOACYP2C9ADRA1AHRH1 | |
| SCHEMBL787526 | 0.73 | CYP2C9 (0.66) | CYP2C9ADRA1AHRH1 | |
| SCHEMBL787515 | 0.73 | CYP2C9 (0.57) | MAOACYP2C9ADRA1AHRH1 | |
| SCHEMBL787655 | 0.73 | CYP2C9 (0.75) | MAOACYP2C9ADRA1AHRH1 | |
| SCHEMBL804299 | 0.72 | MPI (0.67) | CYP2C9 | |
| SCHEMBL787025 | 0.72 | CYP2C9 (0.79) | CYP2C9ADRA1AHRH1 | |
| SCHEMBL804221 | 0.72 | CYP2C9 (0.67) | CYP2C9ADRA1AHRH1 | |
| SCHEMBL31409541 | 0.72 | MAOA (0.59) | MAOACYP2C9ADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | SCN1A 662/4885SCN5A 993/4885SCN9A 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.